Renal sympathetic denervation - a review of applications in current practice

Interventional Cardiology: Reviews, Research, Resources

Volumn 9, Issue 1, 2014, Pages 54-61

  Kapil, Vikas ^a,b   Jain, Ajay K ^a,c   Lobo, Melvin D ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

Devices; Hypertension; Renal sympathectomy; Resistant

Indexed keywords

ALCOHOL; BOTULINUM TOXIN A; GUANETHIDINE; NEUROTOXIN; VINCRISTINE;

ADRENERGIC SYSTEM; ARTICLE; AUTONOMIC DENERVATION; BLOOD PRESSURE REGULATION; BRACHYTHERAPY; CATHETER; CLINICAL PRACTICE; DYSTONIA; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DEVICE; MORBIDITY; MORTALITY; NONHUMAN; PHARMACOLOGICAL PROCEDURES; RADIOFREQUENCY ABLATION; RADIOSURGERY; RENAL SYMPATHETIC DENERVATION; RENAL SYMPATHETIC DENERVATION SYSTEM; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; ROBOTICS; SPASTICITY; SYMPATHETIC TONE; ULTRASOUND THERAPY;

EID: 84901984572     PISSN: 17561477     EISSN: 17561485     Source Type: Journal    
DOI: 10.15420/icr.2011.9.1.54     Document Type: Article

References (98)

1. de La Sierra A, Segura J, Banegas JR, et al., Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring, Hypertension, 2011;57:898-902.
2. Persell SD, Prevalence of resistant hypertension in the United States, 2003-2008, Hypertension, 2011;57:1076-80.
3. Pimenta E, Calhoun DA, Resistant hypertension: incidence, prevalence, and prognosis, Circulation, 2012;125:1594-6.
4. Mancia G, Fagard R, Narkiewicz K, et al., 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 2013;34:2159-2219.
5. National Institute of Clinical Excellence. Hypertension: Clinical Management of Primary Hypertension in Adults. London: Royal College of Physicians, 2011.
6. Calhoun DA, Jones D, Textor S, et al., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 2008;51:1403-19.
7. Daugherty SL, Powers JD, Magid DJ, et al., Incidence and prognosis of resistant hypertension in hypertensive patients, Circulation, 2012;125:1635-42.
8. Kumbhani DJ, Steg PG, Cannon CP, et al., Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis, Eur Heart J, 2013;34:1204-14.
9. Pierdomenico SD, Lapenna D, Bucci A, et al., Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension, Am J Hyp, 2005;18:1422-8.
10. Krum H, Schlaich M, Whitbourn R, et al., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study, Lancet, 2009;373:1275-81.
11. Grassi G, Cattaneo BM, Seravalle G, et al., Baroreflex control of sympathetic nerve activity in essential and secondary hypertension, Hypertension, 1998;31:68-72.
12. Esler M, Lambert G, Jennings G, Regional norepinephrine turnover in human hypertension, Clin Exp Hypertens A, 1989;11 Suppl. 1:75-89.
13. Barajas L, Liu L, Powers K, Anatomy of the renal innervation: intrarenal aspects and ganglia of origin, Can J Physiol Pharmacol, 1992;70:735-49.
14. Atherton DS, Deep NL, Mendelsohn FO, Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study, Clin Anat, 2012;25:628-33.
15. Stella A, Zanchetti A, Functional role of renal afferents, Physiol Rev, 1991;71:659-82.
16. Prosnitz EH, DiBona GF, Effect of decreased renal sympathetic nerve activity on renal tubular sodium reabsorption, Am J Physiol, 1978;235:F557-63.
17. Zimmerman BG, Sybertz EJ, Wong PC, Interaction between sympathetic and renin-angiotensin system, J Hypertens, 1984;2:581-7.
18. Parkes WE, Thoracolumbar sympathectomy in hypertension, Br Heart J, 1958;20:249-52.
19. Smithwick RH, Thompson JE, Splanchnicectomy for essential hypertension; results in 1,266 cases, JAMA, 1953;152:1501-4.
20. Veterans Administration Cooperative Study Group, Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg, JAMA, 1967;202:1028-34.
21. DiBona GF, Kopp UC. Neural control of renal function, Physiol Rev, 1997;77:75-197.
22. Onesti G, Kim KE, Greco JA, et al., Blood pressure regulation in end-stage renal disease and anephric man, Circ Res, 1975;36:145-52.
23. Rippy MK, Zarins D, Barman NC, et al., Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety, Clin Res Cardiol, 2011;100:1095-1101.
24. Huang SK, Bharati S, Graham AR, et al., Closed chest catheter desiccation of the atrioventricular junction using radiofrequency energy - a new method of catheter ablation, J Am Coll Cardiol, 1987;9:349-58.
25. Haines DE, The biophysics of radiofrequency catheter ablation in the heart: the importance of temperature monitoring, Pacing Clin Electrophysiol, 1993;16:586-91.
26. Wittkampf FH, Simmers TA, Hauer RN, et al., Myocardial temperature response during radiofrequency catheter ablation, Pacing Clin Electrophysiol, 1995;18:307-17.
27. Schlaich MP, Schmieder RE, Bakris G, et al., International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension, J Am Coll Cardiol, 2013;62(22):2031-45.
28. Caulfield MJ, de Belder M, Cleveland T, et al., The Joint UK Societies' consensus statement on renal denervation for resistant hypertension, British Hypertension Society, 2012. Available at: http://www.bcs.com/pages/news_full. asp?NewsID=19792021 (accessed 24 February 2014).
29. Schmieder RE, Redon J, Grassi G, et al., ESH position paper: renal denervation - an interventional therapy of resistant hypertension, J Hypertens, 2012;30:837-41.
30. Krum H, Schlaich MP, Böhm M, et al., Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study, Lancet, 2014;383(9917):622-9.
31. Symplicity HTN-2 Investigators, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial, Lancet, 2010;376:1903-9.
32. Hamon M, Pristipino C, Di Mario C, et al., Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology, EuroIntervention, 2013;8:1242-51.
33. Zaman S, Pouliopoulos J, Al Raisi S, et al., Novel use of NavX three-dimensional mapping to guide renal artery denervation, EuroIntervention, 2013;9:687-93.
34. Guo X, Zhai F, Nan Q, The temperature field simulation of radiofrequency catheter-based renal sympathetic denervation for resistant hypertension, Biomed Mater Eng, 2014;24:315-21.
35. Nakagawa H, Yamanashi WS, Pitha JV, et al., Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation, Circulation, 1995;91:2264-73.
36. Sakakura K, Ladich E, Fuimaono K, et al., Comparison of arterial, surrounding soft tissue and nerve damage with irrigated vs. non-irrigated radiofrequency ablation [abstract], J Am Coll Cardiol, 2013;62:B149-50.
37. Templin C, Jaguszewski M, Ghadri JR, et al., Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity(R) catheter system and the EnligHTN™ multi-electrode renal denervation catheter, Eur Heart J, 2013;34:2141-8.
38. Cook S, Goy J-J, Togni M, Optical coherence tomography findings in renal denervation, Eur Heart J, 2012;33:2992.
39. Hering D, Mahfoud F, Walton AS, et al., Renal denervation in moderate to severe CKD, J Am Soc Nephrol, 2012;23:1250-7.
40. Heuser RR, Mhatre AU, Buelna TJ, et al., A novel non-vascular system to treat resistant hypertension, EuroIntervention, 2013;9:135-9.
41. Natale A, Pisano E, Shewchik J, et al., First human experience with pulmonary vein isolation using a through-the-balloon circumferential ultrasound ablation system for recurrent atrial fibrillation, Circulation, 2000;102:1879-82.
42. Kennedy JE, High-intensity focused ultrasound in the treatment of solid tumours, Nat Rev Cancer, 2005;5:321-7.
43. Wang Q, Guo R, Rong S, et al., Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model, J Am Coll Cardiol, 2013;61:2185-92.
44. Feril LB, Kondo T, Biological effects of low intensity ultrasound: the mechanism involved, and its implications on therapy and on biosafety of ultrasound, J Radiat Res, 2004;45:479-89.
45. May O, The functional and histological effects of intraneural and intraganglionic injections of alcohol, Br Med J, 1912;2:465-170.
46. Harris W, Alcohol injection of the Gasserian ganglion for trigeminal neuralgia, Lancet, 1912;179:218-21.
47. Iaccarino V, Russo D, Niola R, et al., Total or partial percutaneous renal ablation in the treatment of renovascular hypertension: radiological and clinical aspects, Br J Radiol, 1989;62:593-8.
48. Jankovic J, Orman J, Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study, Neurology, 1987;37:616-23.
49. Das TK, Park DM, Effect of treatment with botulinum toxin on spasticity, Postgrad Med J, 1989;65:208-10.
50. Yu L, Scherlag BJ, Dormer K, et al., Autonomic denervation with magnetic nanoparticles, Circulation, 2010;122:2653-9.
51. Burnstock G, Evans B, Gannon BJ, et al., A new method of destroying adrenergic nerves in adult animals using guanethidine, Br J Pharmacol, 1971;43:295-301.
52. Manning PT, Powers CW, Schmidt RE, et al., Guanethidineinduced destruction of peripheral sympathetic neurons occurs by an immune-mediated mechanism, J Neurosci, 1983;3:714-24.
53. Casey EB, Jellife AM, Le Quesne PM, et al., Vincristine neuropathy. Clinical and electrophysiological observations, Brain, 1973;96:69-86.
54. Stefanadis C, Synetos A, Toutouzas K, et al., New double balloon delivery catheter for chemical denervation of the renal artery with vincristine, Int J Cardiol, 2013;168:4346-8.
55. Stefanadis C, Toutouzas K, Synetos A, et al., Chemical denervation of the renal artery by vincristine in swine. A new catheter based technique, Int J Cardiol, 2013;167:421-5.
56. Stefanadis C, Toutouzas K, Vlachopoulos C, et al., Chemical denervation of the renal artery with vincristine for the treatment of resistant arterial hypertension: first-in-man application, Hellenic J Cardiol, 2013;54:318-21.
57. Heard BE, Nuclear crystals in slowly frozen tissues at very low temperatures; comparison of normal and ascites tumour cells, Br J Surg, 1955;42:659-63.
58. Cooper IS, Cryogenic surgery: a new method of destruction or extirpation of benign or malignant tissues, N Engl J Med, 1963;89:741-749.
59. Tse H-F, Reek S, Timmermans C, et al., Pulmonary vein isolation using transvenous catheter cryoablation for treatment of atrial fibrillation without risk of pulmonary vein stenosis, J Am Coll Cardiol, 2003;42:752-8.
60. Deisenhofer I, Zrenner B, Yin Yh, et al., Cryoablation versus radiofrequency energy for the ablation of atrioventricular nodal reentrant tachycardia (the CYRANO Study): results from a large multicenter prospective randomized trial, Circulation, 2010;122:2239-45.
61. Prochnau D, Figulla HR, Romeike BFM, et al., Percutaneous catheter-based cryoablation of the renal artery is effective for sympathetic denervation in a sheep model, Int J Cardiol, 2011;152:268-70.
62. Prochnau D, Figulla HR, Surber R, Cryoenergy is effective in the treatment of resistant hypertension in nonresponders to radiofrequency renal denervation, Int J Cardiol, 2013;167:588-90.
63. Stoll BA, Andrews JT, Radiation-induced peripheral neuropathy, Br Med J, 1966;1:834-7.
64. Waksman R, Barbash IM, Chan R, et al., Beta radiation for renal nerve denervation: initial feasibility and safety, EuroIntervention, 2013;9:738-44.
65. Bakris GL, Nadim MK, Haller H, et al., Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial, J Am Soc Hypertens, 2012;6:152-8.
66. Hoppe UC, Brandt MC, Wachter R, et al., Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim Neo trial, J Am Soc Hypertens, 2012;6:270-6.
67. Brouwers S, Dolan E, Galvin J, et al., Creation of an iliofemoral arteriovenous fistula in patients with severe hypertension: a prospective open label multi center pilot study [abstract], J Hypertens, 2013;31:e103.
68. Ukena C, Cremers B, Ewen S, et al., Response and nonresponse to renal denervation: who is the ideal candidate?, EuroIntervention, 2013;9 Suppl. R:R54-7.
69. Persu A, Jin Y, Azizi M, et al., Blood pressure changes after renal denervation at 10 European expert centers, J Hum Hypertens, 2014;28(3):150-6.
70. Worthley SG, Tsioufis CP, Worthley MI, et al., Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial, Eur Heart J, 2013;34:2132-40.
71. Hering D, Lambert EA, Marusic P, et al., Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension, Hypertension, 2013;61:457-64.
72. Zuern CS, Eick C, Rizas KD, et al., Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension, J Am Coll Cardiol, 2013;62(22):2124-30.
73. Hart EC, McBryde FD, Burchell AE, et al., Translational examination of changes in baroreflex function after renal denervation in hypertensive rats and humans, Hypertension, 2013;62:533-41.
74. Pokushalov E, Romanov A, Corbucci G, et al., A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension, J Am Coll Cardiol, 2012;60:1163-70.
75. Jin Y, Thijs L, Persu A, et al., Letter to the Editor: no support for renal denervation in a meta-analysis, J Am Coll Cardiol, 2013;62:2029-30.
76. Persu A, Renkin J, Thijs L, et al., Renal denervation: ultima ratio or standard in treatment-resistant hypertension, Hypertension, 2012;60:596-606.
77. Staessen JA, Jin Y, Thijs L, et al., First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern, J Am Coll Cardiol, 2013;62:e445-6.
78. Howard JP, Nowbar AN, Francis DP, Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report, Heart, 2013;99:1579-87.
79. Kaltenbach B, Franke J, Bertog SC, et al., Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study, Catheter Cardiovasc Interv, 2013;81:335-9.
80. Ott C, Mahfoud F, Schmid A, et al., Renal denervation in moderate treatment resistant hypertension, J Am Coll Cardiol, 2013;62:1880-6.
81. Gazdar AF, Dammin GJ, Neural degeneration and regeneration in human renal transplants, N Engl J Med, 1970;283:222-4.
82. Blaufox MD, Lewis EJ, Jagger P, et al., Physiologic responses of the transplanted human kidney: sodium regulation and renin secretion, N Engl J Med, 1969;280:62-6.
83. Davies JE, Manisty CH, Petraco R, et al., First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study, Int J Cardiol, 2013;162:189-92.
84. Brandt MC, Mahfoud F, Reda S, et al., Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension, J Am Coll Cardiol, 2012;59:901-9.
85. Witkowski A, Prejbisz A, Florczak E, et al., Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea, Hypertension, 2011;58:559-65.
86. Mahfoud F, Schlaich M, Kindermann I, et al., Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study, Circulation, 2011;123:1940-46.
87. Ukena C, Bauer A, Mahfoud F, et al., Renal sympathetic denervation for treatment of electrical storm: first-in-man experience, Clin Res Cardiol, 2012;101:63-7.
88. Whitbourn R, Harding S, Rothman M, et al., Renal artery denervation with a new simultaneous multielectrode catheter for treatment of resistant hypertension: results from the Symplicity Spyral first-in-man study [abstract], J Am Coll Cardiol, 2013;62:B150.
89. Ormiston JA, Watson T, van Pelt N, et al., Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial, EuroIntervention, 2013;9:70-4.
90. Ahmed H, Neuzil P, Skoda J, et al., Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension, JACC Cardiovasc Interv, 2012;5:758-65.
91. Mazor M, Baird R, Stanley J, Evaluation of acute, sub-acute, and chronic renal artery nerve morphological changes following bipolar radiofrequency renal denervation treatment in the porcine model [abstract], J Am Coll Cardiol, 2013;62:B150.
92. Honton B, Pathak A, Sauguet A, et al., First report of transradial renal denervation with the dedicated radiofrequency Iberis™ catheter, EuroIntervention, 2013; [Epub ahead of press].
93. Ladich E, Coleman L, Cabane V, et al., Arterial media preservation associated with the paradise ultrasound renal denervation system: a next generation approach for treating resistant hypertension [abstract], J Am Coll Cardiol, 2013;62:B151-2.
94. Mabin T, Sapoval M, Cabane V, et al., First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension, EuroIntervention, 2012;8:57-61.
95. Neuzil P, Petru J, Vondrakova D, et al., Circumferential therapeutic ultrasound for the treatment of resistant hypertension: preliminary results of human feasibility study (SOUND-ITV) [abstract], J Am Coll Cardiol, 2012;60:B101-2.
96. Neuzil P, Whitbourn RJ, Starek Z, et al., Optimized external focused ultrasound for renal sympathetic denervation - wave ii trial [abstract], J Am Coll Cardiol, 2013;62:B20-B20.
97. Owens CD, Gasper WJ, Rousselle S, et al., Peri-adventitial renal artery delivery of guanethidine monosulfate attenuates renal nerve function: preclinical experience and implication for resistant hypertension [abstract], J Am Coll Cardiol, 2011;58:B120.
98. Fischell TA, Vega F, Raju N, et al., Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model, EuroIntervention, 2013;9:140-7.